Merck & Co., Inc. $MRK Stock Position Lessened by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund reduced its position in shares of Merck & Co., Inc. (NYSE:MRK) by 1.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 373,534 shares of the company’s stock after selling 6,452 shares during the period. Merck & Co., Inc. comprises about 0.6% of Illinois Municipal Retirement Fund’s investment portfolio, making the stock its 18th biggest position. Illinois Municipal Retirement Fund’s holdings in Merck & Co., Inc. were worth $54,278,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Brooklyn FI LLC bought a new position in Merck & Co., Inc. in the 3rd quarter valued at $346,000. Moneco Advisors LLC boosted its stake in Merck & Co., Inc. by 3.8% in the third quarter. Moneco Advisors LLC now owns 19,603 shares of the company’s stock worth $2,849,000 after purchasing an additional 709 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its holdings in shares of Merck & Co., Inc. by 4.0% during the third quarter. Mesirow Financial Investment Management Inc. now owns 40,929 shares of the company’s stock worth $5,948,000 after purchasing an additional 1,578 shares during the last quarter. Cornerstone Wealth Management LLC grew its holdings in shares of Merck & Co., Inc. by 5.2% during the third quarter. Cornerstone Wealth Management LLC now owns 23,427 shares of the company’s stock worth $3,404,000 after purchasing an additional 1,154 shares during the last quarter. Finally, Csenge Advisory Group grew its holdings in shares of Merck & Co., Inc. by 3.3% during the third quarter. Csenge Advisory Group now owns 14,478 shares of the company’s stock worth $2,104,000 after purchasing an additional 467 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported positive Phase 2b results for efinopegdutide in patients with MASH and moderate-to-advanced liver fibrosis. The investigational drug could broaden Merck’s future growth opportunities, though it remains in clinical development. Article
• Positive Sentiment: Merck started a Phase 3 trial of OHTUVAYRE for COPD maintenance and said the FDA granted priority review to sacituzumab tirumotecan for endometrial cancer. Progress across these programs could support its pipeline, although neither development guarantees commercial success. Article
• Neutral Sentiment: A dividend-stock comparison notes that Merck and Gilead raised their 2026 sales outlooks after third-quarter results. It offers limited new company-specific information about MRK beyond that update. Article
• Neutral Sentiment: The reported FDA approval of PIMJETMI (pimicotinib) concerns Merck KGaA, the Germany-based company—not Merck & Co. (MRK)—so it should not be treated as a direct catalyst for MRK. Article
• Negative Sentiment: Analyst commentary warns that 2027 growth could be pressured by generic competition, weaker vaccine demand and slowing Keytruda growth. Those risks may weigh on near-term expectations, even as Merck’s expanding pipeline offers longer-term potential. Article

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on MRK shares. Scotiabank raised their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the company a “sector outperform” rating in a research note on Tuesday, September 29th. Argus began coverage on shares of Merck & Co., Inc. in a research report on Tuesday, November 3rd. They set a “strong-buy” rating on the stock. BMO Capital Markets increased their price objective on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, August 20th. Wells Fargo & Company increased their price objective on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. Finally, Wall Street Zen upgraded shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $155.74.

Insider Activity at Merck & Co., Inc.

In other news, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the sale, the executive vice president directly owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. This trade represents a 21.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Stock Performance

MRK stock opened at $148.00 on Wednesday. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14. The company has a 50 day moving average price of $146.39 and a 200 day moving average price of $128.02. Merck & Co., Inc. has a fifty-two week low of $87.26 and a fifty-two week high of $156.92. The stock has a market capitalization of $364.85 billion, a PE ratio of 152.57, a price-to-earnings-growth ratio of 6.78 and a beta of 0.13.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The firm had revenue of $18.09 billion for the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter in the prior year, the business earned $2.58 EPS. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. Analysts forecast that Merck & Co., Inc. will post 2.84 EPS for the current year.

About Merck & Co., Inc.

Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.